OV announces prolongation of option to buy back shares in OV SPV2 that holds TKI product from BigPharma
On November 16, 2017, Oncology Venture Sweden AB ("Oncology Venture") has agreed with one of the major investors in OV-SPV2 ApS to prolong the option to buy back shares in OV-SPV2 that holds the TKI product from Novartis. The option will be prolonged with six (6) months – until June 1st 2018. The major investor wishes to maintain an ownership of 15% in OV-SPV2 ApS.Option agreement Oncology Venture announced on the 23rd October that data on the TKI project from Novartis is expected to be published within 6-8 weeks. The major investor and Oncology Venture has agreed to prolong Oncology